Purple Biotech announced that the first patient has been dosed in the randomized part of the open label Phase 2 clinical trial evaluating CM24 in the treatment of advanced metastatic pancreatic cancer, PDAC. "We are excited with the progress made in this study as we start its randomized part," said Gil Efron, Chief Executive Officer of Purple Biotech. "Patients with metastatic pancreatic cancer such as those we are enrolling in our ongoing trial have very few therapeutic options, with relatively short duration of survival. If this study is successful, it may open a path for a short time to market."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PPBT:
- Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
- Purple Biotech reports Q4 EPS (33c) vs (29c) last year
- Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results
- Purple Biotech enters agreement to acquire Immunorizon
- Purple Biotech, Mor Research Applications enter oncology collaboration